Mr. Gilles Gagnon reports

CEAPRO INC. REPORTS 2016 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Ceapro Inc. has declared its financial results for the three months ended March 31, 2016, and is providing a business update.

Financial highlights for the first quarter of 2016:

• Best first quarter performance with revenues reaching historical highs;
• Total sales of $4,064,000 for the quarter ended March 31, 2016, compared with $1,714,000 in 2015, a 137-per-cent increase of quarter-over-quarter revenue performance;
• Record income from operations of $1.91-million for the quarter ended March 31, 2016, compared with a loss from operations of $226,000 in 2015;
• Net profit after taxes of $1,213,000 for the quarter ended March 31, 2016, compared with a net loss of $194,000 for 2015;
• Cash flows generated from operations for the quarter ended March 31, 2016, of $2,273,000 compared with a cash burn of $173,000 for the same period in 2015.

Gilles Gagnon, MSc, MBA, president and chief executive officer of Ceapro, stated: "We are very pleased with ending the first quarter of 2016 with these exceptional results and aim to continue to drive value in our high-value derisked base business in cosmeceuticals, which has shown to be a proven result of the effectiveness of our business strategy.

"With these results combined with the recent announcement of the renewal of a long-term agreement with our major distributor, Symrise AG, Ceapro has established a solid base for year-over-year growth. Beyond these excellent financial results, we will continue to develop our pipeline and execute our projects rigorously toward market expansion into the profitable nutraceutical and pharmaceutical sectors as we anticipate top-line data from our beta glucan study and our avenanthramides bioavailability study, and our expected launch of Ceapro's first two clinical studies this year with these two important value drivers."

Recent corporate highlights:

• Presented its PGX technology at the prestigious 15th European Meeting on Supercritical Fluids;
• Received issuance of a U.S. patent for Ceapro's unique and disruptive enabling pressurized-gas-expanded (PGX) technology covering proprietary methods and use of microsized and nanosized particles generated by applying PGX supercritical fluid technology;
• Signed a research agreement with McMaster University for testing of materials using PGX technology;
• Renewed a major distribution agreement with long-time partner, Symrise AG.

"We fully believe our unique and disruptive enabling PGX technology will expand our reach into additional high-value programs and facilitate beneficial strategic collaborations in a broad range of industrial applications. The broad utility of this technology is an important part of Ceapro's growth strategy," concluded Mr. Gagnon.

Avenanthramides update

Due to an enabling technology in-licensed from Agriculture Canada, Ceapro successfully produced three batches at the commercial level in its current facility for a next generation of avenanthramides extracted from malted oat. As part of the international application of the Patent Cooperation Treaty (PCT), the company has already been issued patents in both Canada and China for avenanthramides resulting from this enabling malting technology.

Ceapro is currently assessing avenanthramides in a bioavailability study with a United States-based university to compare low-dose and high-dose avenanthramides. The company fully expects the bioavailability study to further demonstrate the efficacy of avenanthramides in alleviating exercise-induced inflammation as evidenced by a lack of inflammation biomarkers shown previously in published data from a study in elderly people. If additional positive trends are observed, Ceapro expects to commence its clinical program with avenanthramides as an anti-inflammatory compound before year-end.

Beta glucan update

Following the successful impregnation study conducted at MIT, Ceapro has initiated a study with the University of Alberta for the development of a prototype formulation for a functional drink whereby the company has impregnated beta glucan with the co-enzyme Q10 as an energy booster. Ceapro anticipates that the development of the impregnated prototype for functional drink will be completed by the end of 2016.

The company plans to initiate a pilot clinical study to develop beta glucan as a cholesterol reducer in the third quarter of 2016. Previously existing safety and toxicology studies demonstrate a positive safety profile for beta glucan in more than 200,000 individuals from an industry partner currently commercializing beta glucan as a carrier in a urinary incontinence device. Ceapro will also conduct its own safety studies to assess high-purity oral beta glucan during the second quarter of 2016.

PGX research programs update

Ceapro is developing its in-licensed PGX enabling technology at the commercial-scale level for all industries and all applications. The company has been issued a U.S. patent covering proprietary methods and use of microsized and nanosized particles generated by applying PGX supercritical fluid technology.

The company has conducted encouraging lab-scale research with PGX and analyzed biopolymer samples from commercially available starch, pectin, gums, alginate and other polymers from various multinational companies in a broad range of industries. Ceapro is evaluating potential collaborations and alliance opportunities with these companies.

Financial results for three-month period ended March 31, 2016:

• Total revenue of $4,064,000 for the three months ended March 31, 2016, compared with $1,714,000 for the three-month period ended March 31, 2015, an increase of 137 per cent primarily as a result of higher sales volumes of beta glucan in Europe and Asia, and strong sales of the company's flagship product, avenanthramides. Total revenues were also positively impacted by a stronger U.S. dollar relative to the Canadian dollar;
• Net income before tax was $1,734,000 for the three months ended March 31, 2016, compared with a loss of $230,000 for the same period in 2015;
• Net profit after taxes of $1,213,000 for the quarter ended March 31, 2016, compared with a net loss of $194,000 for 2015;
• Research and development investments of $328,000 for the three-month period ended March 31, 2016, compared with $106,000 in the 2015 period;
• General and administration expenses of $496,000 for the three months ended March 31, 2016, compared with $802,000 for the same period in 2015. The decrease in G&A in 2016 compared with 2015 is mostly due to lower salaries and benefits expense as the company did not have a significant option granting so the share-based payment charges were considerably lower. The other significant decrease is related to lower legal fees as the AVAC trial was completed in the first quarter of 2015 and there were no corresponding legal fees in the first quarter of 2016;
• Sales and marketing expenses for the three months ending March 31, 2016, of only $2,000 compared with $3,000 in 2015 due to the company's sales strategy to sell mostly through a distribution network;
• As of March 31, 2016, the company had cash and cash equivalents of $1,999,194 as compared with $1,681,125 as of Dec. 31, 2015.

                                                                                                                                            
CONSOLIDATED STATEMENTS OF NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)

                                                 Three months ended March 31,
                                                          2016          2015

Revenue                                             $4,063,576    $1,714,485
Cost of goods sold                                   1,229,763       922,386
                                                    ----------    ----------
Gross margin                                         2,833,813       792,099
Research and product development                       327,832       105,907
General and administration                             495,646       801,933
Sales and marketing                                      2,186         3,167
Finance costs                                           98,481       106,750
                                                    ----------    ----------
Income (loss) from operations                        1,909,668      (225,658)
Other operating (loss)                                (175,692)       (4,430)
                                                    ----------    ----------
Income (loss) before tax                             1,733,976      (230,088)
Income taxes
Current tax expense                                   (458,006)            -
Deferred tax (expense) recovery                        (62,578)       36,250
                                                    ----------    ----------
Income tax (expense) recovery                         (520,584)       36,250
Total comprehensive income (loss) for the period     1,213,392      (193,838)
                                                    ==========    ==========
Net income (loss) per common share
Basic                                                     0.02         (0.00)
                                                    ----------    ----------
Diluted                                                   0.02         (0.00)
                                                    ==========    ==========

The complete financial statements are available for review on SEDAR and on the company's website.